NEW YORK, NY / ACCESSWIRE / October 1, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Yalla Group Limited (NYSE:YALA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/yalla-group-limited-loss-submission-form?prid=20042&wire=1
Lead Plaintiff Deadline: October 12, 2021
Class Period: September 30, 2020 - August 9, 2021
Allegations against YALA include that: the Company overstated its user metrics and revenue and, as a result, the Company's public statements were materially false and misleading at all relevant times.
Koninklijke Philips N.V. (NYSE:PHG)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?prid=20042&wire=1
Lead Plaintiff Deadline: October 15, 2021
Class Period: February 25, 2020 - June 11, 2021
Allegations against PHG include that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Annovis Bio, Inc. (NYSE:ANVS)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=20042&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: May 21, 2021 - July 28, 2021
Allegations against ANVS include that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong